575.20
-7.86 (-1.35%)
| Previous Close | 583.06 |
| Open | 584.47 |
| Volume | 201,269 |
| Avg. Volume (3M) | 521,867 |
| Market Cap | 45,799,743,488 |
| Price / Earnings (TTM) | 44.04 |
| Price / Earnings (Forward) | 39.68 |
| Price / Sales | 10.73 |
| Price / Book | 28.20 |
| 52 Weeks Range | |
| Earnings Date | 5 May 2026 |
| Profit Margin | 22.76% |
| Operating Margin (TTM) | 31.70% |
| Diluted EPS (TTM) | 10.82 |
| Quarterly Revenue Growth (YOY) | 3.60% |
| Quarterly Earnings Growth (YOY) | 3.00% |
| Total Debt/Equity (MRQ) | 73.16% |
| Current Ratio (MRQ) | 1.16 |
| Operating Cash Flow (TTM) | 968.38 M |
| Levered Free Cash Flow (TTM) | 761.15 M |
| Return on Assets (TTM) | 22.98% |
| Return on Equity (TTM) | 59.33% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Diagnostics & Research (US) | Mixed | Bullish |
| Diagnostics & Research (Global) | Mixed | Bullish | |
| Stock | IDEXX Laboratories, Inc. | Bearish | Bullish |
AIStockmoo Score
| Analyst Consensus | 1.0 |
| Insider Activity | NA |
| Price Volatility | 1.0 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | -2.0 |
| Average | 0.00 |
|
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets close to 35% of its revenue from outside the United States. |
|
| Sector | Healthcare |
| Industry | Diagnostics & Research |
| Investment Style | Mid Growth |
| % Held by Insiders | 0.67% |
| % Held by Institutions | 97.51% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Elyxium Wealth, Llc | 31 Dec 2025 | 5,419,507 |
| Polen Capital Management Llc | 31 Dec 2025 | 960,537 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 800.00 (Barclays, 39.08%) | Buy |
| 800.00 (BTIG, 39.08%) | Buy | |
| Median | 775.00 (34.74%) | |
| Low | 730.00 (UBS, 26.91%) | Hold |
| Average | 770.00 (33.87%) | |
| Total | 2 Buy, 2 Hold | |
| Avg. Price @ Call | 637.13 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Piper Sandler | 09 Feb 2026 | 750.00 (30.39%) | Hold | 639.79 |
| Barclays | 05 Feb 2026 | 800.00 (39.08%) | Buy | 643.59 |
| BTIG | 03 Feb 2026 | 800.00 (39.08%) | Buy | 632.56 |
| UBS | 03 Feb 2026 | 730.00 (26.91%) | Hold | 632.56 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 02 Feb 2026 | Announcement | IDEXX Laboratories Announces Fourth Quarter and Full Year 2025 Results |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |